Slow Enrollment Frustrates Mesothelioma Trial of Imfinzi

According to a report presented at the 2025 ESMO Congress, mesothelioma patients treated with first-line Imfinzi (durvalumab) plus chemotherapy achieved a median overall survival of 21 months compared to 18 months with chemotherapy alone in the phase 3 DREAM3R study. However, slow patient enrollment and shifting standards of treatment complicated the study’s protocol, leading to

The post Slow Enrollment Frustrates Mesothelioma Trial of Imfinzi appeared first on Mesothelioma.net.

from Mesothelioma.net https://ift.tt/lzXCqGj
via IFTTT